After Q4 sales sink, Amgen CEO Bob Bradway details lofty growth strategy for 2030: Can he pull it off?
While Amgen boasted a 2% revenue boost last year, that growth was largely driven by profits from the company’s Covid-19 manufacturing deal with Eli Lilly, the company revealed in its Q4 results. To make up for declining Q4 sales, CEO Bob Bradway outlined a lofty growth strategy for the next decade.
The only question now is: Will he be able to pull it off?
Instead of holding a Q4 call with investors, Bradway hosted a three-and-a-half-hour-long business review in which he laid out his plans for the rest of the decade — which include investment in the company’s internal pipeline and potentially some M&A as all signs point to an impending Big Pharma deal hunt.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
